RANCHO CUCAMONGA, CA--(Marketwired - Apr 18, 2017) - Proto Script Pharmaceutical Corp. dba PSP Homecare ("PSP" or the "Company") (OTC PINK: PSCR), a durable medical equipment provider, is pleased to announce that the Company has entered into a Supply Agreement with PAKmed LLC ("PAKmed"), a manufacturer of premium orthotic braces based in Louisville, Kentucky.
Under terms of the Supply Agreement, PAKmed will provide PSP certain premium orthotic braces for shipment to patient customers, as directed by PSP. The Supply Agreement specifically covers five (5) of the most commonly prescribed types of orthotic braces in the United States and sets price per brace including shipping costs.
"We are very pleased to have come to a long term nationwide direct-to-patient supply agreement with a leading American manufacturer of orthotic braces," commented Michelle Rico, CEO of Proto Script Pharmaceutical Corp. "Established supply agreements like this one enable PSP to continue to efficiently expand its product offerings while allowing us to focus our resources on reaching out to new potential patients across the country."
Further details regarding PSP Homecare's sales and marketing strategy and other updates will be made as additional information becomes available.
About Proto Script Pharmaceutical Corp.
Proto Script Pharmaceutical Corp. dba PSP Homecare provides a comprehensive collection of durable medical equipment (DME) like canes, crutches, walkers, commodes, patient lifts, hospital beds, orthotics (braces), wheelchairs, scooters, power wheelchairs, rehabilitation equipment, and accessories. Currently serving California and Nevada, PSP Homecare has specialized in the repair of power wheelchairs and the sale of orthotics since 2011. The Company deals with a growing list of federal, state and private insurance providers such as Medicare, Medi-Cal, Nevada Care and Blue Cross among several others.
Additional information regarding PSP Homecare can be found at www.psphomecare.com.
Proto Script Pharmaceutical Corp. files reports with the Securities & Exchange Commission on EDGAR and anticipates continuing to file such reports. The Company's filings can be viewed at www.sec.gov.
Cautionary Language Concerning Forward-Looking Statements
This Proto Script Pharmaceutical Corp. press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including those with respect to the Company's mission statement and growth strategy, are "forward-looking statements." Although the Company's management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties, which could cause the Company's future results to differ materially from those anticipated. Potential risks and uncertainties include, among others, general economic conditions and conditions affecting the industries in which the Company operates; the uncertainty of regulatory requirements and approvals; and the ability to obtain necessary financing on acceptable terms or at all. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update any of the information contained or referenced in this press release.